Scholarlink

<p>Electrical stimulation (ES) may be effective for intractable retinal or optic nerve diseases. We studied frequent transcutaneous ES in a single-center, single-arm prospective study in patients with Leber hereditary optic neuropathy (LHON) who carry the mitochondrial (mt) 11778 G &gt; A mutation. A 30-min ES was applied to either eye every other day for 12 weeks. The primary outcome was the difference in the logarithm of the minimum angle of resolution (LogMAR) at baseline and 1 week after completion of ES treatment. The secondary outcomes included changes in visual field; LogMAR; critical flicker frequency; and inner retinal thickness. Safety endpoints included the corneal endothelial cell density and complications during ES. Fourteen patients participated in the study; four dropped out. The median (interquartile range) LogMAR values before stimulation and 1, 4, and 8 weeks after ES were 1.60 (1.45–1.80), 1.70 (1.35–1.80), 1.60 (1.43–1.73), and 1.50 (1.43–1.73), respectively, indicating no significant improvement (primary outcome: Wilcoxon’s signed rank test, <i>p</i> = 1.000, secondary outcome: Friedman test, <i>p</i> = 0.229). There were no improvements in any secondary efficacy endpoints and no complications. In conclusion, frequent transcutaneous ES did not improve visual acuity in patients with LHON carrying the mt11778 G &gt; A mutation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

An exploratory study to evaluate efficacy and safety of frequent Transcutaneous Electrical Stimulation for Leber Hereditary Optic Neuropathy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月9日

查看全文
  • Fumio Takano,
  • Kaori Ueda,
  • Takuji Kurimoto,
  • Mina Arai,
  • Takayuki Nagai,
  • Yuko Yamada-Nakanishi,
  • Makoto Nakamura

摘要

Electrical stimulation (ES) may be effective for intractable retinal or optic nerve diseases. We studied frequent transcutaneous ES in a single-center, single-arm prospective study in patients with Leber hereditary optic neuropathy (LHON) who carry the mitochondrial (mt) 11778 G > A mutation. A 30-min ES was applied to either eye every other day for 12 weeks. The primary outcome was the difference in the logarithm of the minimum angle of resolution (LogMAR) at baseline and 1 week after completion of ES treatment. The secondary outcomes included changes in visual field; LogMAR; critical flicker frequency; and inner retinal thickness. Safety endpoints included the corneal endothelial cell density and complications during ES. Fourteen patients participated in the study; four dropped out. The median (interquartile range) LogMAR values before stimulation and 1, 4, and 8 weeks after ES were 1.60 (1.45–1.80), 1.70 (1.35–1.80), 1.60 (1.43–1.73), and 1.50 (1.43–1.73), respectively, indicating no significant improvement (primary outcome: Wilcoxon’s signed rank test, p = 1.000, secondary outcome: Friedman test, p = 0.229). There were no improvements in any secondary efficacy endpoints and no complications. In conclusion, frequent transcutaneous ES did not improve visual acuity in patients with LHON carrying the mt11778 G > A mutation.